This non-promotional website
has been fully developed and sponsored by AstraZeneca.
This content is intended for healthcare professionals only.
Are you a healthcare professional?
Welcome
References: 1. Roviello G, Catalano M, Santi R, et al. Neoadjuvant treatment in muscle-invasive bladder cancer: from the beginning to the latest developments. Front Oncol. 2022;12:912699. 2. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. N Engl J Med. 2003;349(9):859-66. 3. Dash A, Pettus JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113(9):2471-7. 4. Choueiri TK, Jacobus S, Bellmunt J. et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32(18):1889-94. 5. Yuh BE, Ruel N, Wilson TG, Vodelsang N, Pal SK. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol. 2013;189(5):1682-6. 6. Holzbeierlein J, Bixler BR, Buckley DI et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol. 2024;212(1):3-10. 7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer. V.4.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 10, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. 8. Powles T, Bellmut J, Comperat E, et al on behalf of the ESMO Guidelines Committee. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244-258. 9. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. 10. Kim KH, Lee HW, Ha HK, Seo HK. Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies. Investig Clin Urol. 2023;64(3):202-218.
